Finanzen von Evommune Inc (EVMN)EVMNEvommune Inc

Evaluating the bottom line, Evommune, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -178.02%, provide a clear picture of how effectively EVMN converts its operational activities into shareholder value.

In the context of the broader market, EVMN competes directly with industry leaders such as PBYI and RLMD. With a market capitalization of $531.68M, it holds a leading position in the sector. When comparing efficiency, EVMN's gross margin of N/A stands against PBYI's 77.88% and RLMD's N/A. Such benchmarking helps identify whether Evommune, Inc. is trading at a premium or discount relative to its financial performance.

Evommune reported a net income loss of $32,246,000 in Q2 2026 and has shown no revenue in the last two quarters, indicating significant financial strain. Gross margin has dropped to 0% in recent quarters, reflecting challenges in maintaining profitability.